动物造模,-双歧杆菌,慢性酒精性肝损伤 z-bo 2020-09-09 388

　　Objective: How to study the protection or influence of bifidobacteria (BIFI) on liver function in rats with chronic alcoholic liver injury (chronic alcoholic liver injury, CALI), and preliminarily explore its mechanism?

　　Methods: SD rats were randomly divided into CALI group, metadoxine (90mg/kg) group, BIFI low (500mg/kg), medium (1000mg/kg), high (2000mg/kg) dose groups, and silent information adjustment Protein 1 (silencing information regulatory protein SIRT1) inhibitor Tenovin-6 (25mg/kg) group? Did the CALI group and the blank control group receive the same amount of saline intragastrically? After 8 weeks, analyze the liver function of each group; detect the level of TGγTC in liver tissue and serum; hematoxylin-eosin (HE) staining to observe the pathological changes of liver tissue; SIRT1? Western blot (WB) method is used to analyze the expression of chREBP?

　　Result: Compared with the control group, the liver function of the rats in the CALI group was significantly decreased, and the levels of ALT and AST in the blood were significantly increased. High (P\u003c0.05), liver tissue shows fat pathological damage, liver tissue and serum TG? The level of TC was significantly increased (P\u003c0.05), the expression of SIRT1 protein was significantly reduced (P\u003c0.05), and the expression of chREBP protein was significantly increased (P\u003c0.05). .05); Compared with the CALI group, the liver function of the CALI group in the BIFI medium and low dose group was significantly enhanced, the blood ALT and AST levels were significantly reduced (P\u003c0.05), and the pathological damage to the liver tissue was greatly reduced. The levels of TG and TC in liver tissue and serum were significantly reduced (P\u003c0.05), the expression of SIRT1 protein was significantly increased (P\u003c0.05), and the expression of chREBP protein was significantly reduced. I did it (P\u003c0.05). All of the above effects may be a specific inhibitor of SIRT1 reversal by Tenovin 6α.

　　Conclusion: Can BIFI regulate the expression of SIRT1/ChREBP to inhibit lipid accumulation and protect rats with chronic alcoholic liver injury?